RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Knight Therapeutics Stock

Knight Therapeutics Stocks 2025

Knight Therapeutics Stocks

101.44 M

Ticker

GUD.TO

ISIN

CA4990531069

WKN

A1XE7A

In 2025, Knight Therapeutics had 101.44 M outstanding stocks, a 0% change from the 101.44 M stocks in the previous year.

The Knight Therapeutics Stocks history

YEARNUMBER OF STOCKS (M CAD)
2030e101.44
2029e101.44
2028e101.44
2027e101.44
2026e101.44
2025e101.44
2024101.44
2023107.47
2022114.89
2021124.52
2020132
2019140.1
2018143.3
2017143.4
2016121.3
201596.5
201457.3

Knight Therapeutics shares outstanding

The number of shares was Knight Therapeutics in 2024 — This indicates how many shares 101.437 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Knight Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Knight Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Knight Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Knight Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Knight Therapeutics Aktienanalyse

What does Knight Therapeutics do?

Knight Therapeutics Inc is a Canadian biopharmaceutical company that was founded in 2014. The company is listed on the Toronto Stock Exchange and NASDAQ, making it accessible to all investors. The company's business philosophy is based on the "Acquire and Develop" model, which involves developing acquired products or products that were previously in the approval phase for market testing. Knight Therapeutics focuses on the development and commercialization of pharmaceutical products in Latin America and Canada. The company has gained overseas experience by signing long-term agreements with significant international pharmaceutical companies, including a Japanese and a South Korean pharmaceutical company. In Canada, Knight is in a position to meet the increased demand for innovative drug research and provide patients with important therapies. In Latin America, they focus on achieving broader access to innovative drugs. In this regard, the company is actively working to expand its portfolio of safe, high-quality, and effective medications for this region. The company's product range includes a wide range of priority pharmaceutical areas such as cancer treatments, eye diseases, cardiology, infectious diseases, and pain relief. The company has the expertise to manufacture and distribute specialized treatment options for many diseases, such as cancer and rare diseases. One of Knight Therapeutics' most well-known products is the drug Probuphine. It was approved by the US Food and Drug Administration in May 2016 to help patients with opioid dependence. Knight acquired the product under license from the manufacturer Braeburn Pharmaceuticals. Permian LLC, a real estate fund specializing in retail properties, attempted to acquire Knight with a $150 per share offer. However, this deal was rejected due to Knight's stock dilutions. Another important product of the company is Neuragen, which is used for neuropathic pain and fibromyalgia. It is currently approved in Canada and Brazil, but approvals in the US and other countries are also being sought. Furthermore, Knight Therapeutics is also involved in the manufacturing of generic narcotics and has already concluded some potentially profitable contracts to introduce these products into the Latin American pharmaceutical market. The company has also signed an extremely promising agreement with SAI Life Sciences to develop compounds for the treatment of pain and inflammation. Knight Therapeutics' roadmap also includes a strong partnership with Canadian company Triumvira Immunologics for the further development of cancer treatments, as well as a collaboration with Endoceutics to introduce Prasterone, a superior treatment for vaginal atrophy, menopausal symptoms, and hot flashes in women, to increase bone density and improve sexual life. Overall, Knight Therapeutics has a solid reputation as an emerging player in the pharmaceutical market and is known for its advanced research and development of drugs, with a particular focus on oncology, ophthalmology, and cardiology. It remains to be seen how the company will develop in the future, but it appears that with the aggressive development of innovative products and the expansion into new markets, Knight has great potential to increase its market share in the pharmaceutical industry as a whole. Knight Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Knight Therapeutics's Shares Outstanding

Knight Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Knight Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Knight Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Knight Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Knight Therapeutics stock

How many stocks are there of Knight Therapeutics?

The current number of stocks of Knight Therapeutics is 101.44 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Knight Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Knight Therapeutics evolved in recent years?

The number of shares of Knight Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Knight Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Knight Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Knight Therapeutics pay?

Over the past 12 months, Knight Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Knight Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Knight Therapeutics?

The current dividend yield of Knight Therapeutics is .

When does Knight Therapeutics pay dividends?

Knight Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Knight Therapeutics?

Knight Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Knight Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Knight Therapeutics located?

Knight Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Knight Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Knight Therapeutics from 9/2/2025 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/2/2025.

When did Knight Therapeutics pay the last dividend?

The last dividend was paid out on 9/2/2025.

What was the dividend of Knight Therapeutics in the year 2024?

In the year 2024, Knight Therapeutics distributed 0 CAD as dividends.

In which currency does Knight Therapeutics pay out the dividend?

The dividends of Knight Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Knight Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Knight Therapeutics

Our stock analysis for Knight Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Knight Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.